Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-07-16Clinical Trial Update: Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) [Phase 2]
A Phase 2 trial evaluating eltrombopag for immune thrombocytopenia occurring in patients with chronic lymphoproliferative disorders has comp…
-
CLINICAL_TRIALS trial_result · 2018-07-13Clinical Trial Update: Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance [Phase 2]
Phase 2 trial of ibritumomab tiuxetan (Zevalin) with rituximab maintenance in non-Hodgkin's lymphoma was terminated; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-07-09Clinical Trial Update: Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides [Phase 3]
Phase 3 study evaluating ultraviolet light therapy using methoxsalen with or without bexarotene for mycosis fungoides; the trial was termina…
-
CLINICAL_TRIALS trial_result · 2018-07-06Clinical Trial Update: IMPACT Non Hodgkins Lymphoma (NHL) Study
Amgen's IMPACT trial in non-Hodgkin's lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2018-07-05Clinical Trial Update: Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants [Phase 1]
Phase 1 clinical trial evaluating donor T-helper 2 (Th2) cell therapy to prevent graft-versus-host disease after bone marrow transplantation…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-07-05Clinical Trial Update: MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma [Phase 3]
A Phase 3 trial evaluating safety of switching from intravenous to subcutaneous rituximab during first-line treatment for lymphoma shows com…
-
CLINICAL_TRIALS trial_result · 2018-06-25Clinical Trial Update: Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating combination chemotherapy with pralatrexate as first-line therapy for non-Hodgkin lymphomas, including various T-cel…
-
CLINICAL_TRIALS trial_result · 2018-06-19Clinical Trial Update: Music & Cancer - Live Music During Chemotherapy [NA]
This clinical trial update reports the completion of a study evaluating live music during chemotherapy for patients with non-Hodgkin lymphom…
-
CLINICAL_TRIALS trial_result · 2018-06-06Clinical Trial Update: Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
The National Cancer Institute-sponsored clinical trial assessing relapse in malignant blood cancers after allogeneic hematopoietic stem cell…
-
CLINICAL_TRIALS trial_result · 2018-06-04Clinical Trial Update: AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma [Phase 1]
Phase 1 clinical trial update on AR-42 in adults with advanced or relapsed multiple myeloma, chronic lymphocytic leukemia, and various lymph…
-
CLINICAL_TRIALS trial_result · 2018-05-29Clinical Trial Update: Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies [Phase 1]
Phase I trial update of milatuzumab (anti-CD74/hLL1) antibody therapy in B cell malignancies, including non-Hodgkin lymphoma and chronic lym…
-
CLINICAL_TRIALS trial_result · 2018-05-24Clinical Trial Update: Safety and Efficacy Evaluation of Decitabine With R-GDP [Phase 1]
Phase 1 study evaluating the safety and preliminary efficacy of decitabine in combination with the R-GDP regimen for non-Hodgkin lymphoma.
-
CLINICAL_TRIALS trial_result · 2018-05-18Clinical Trial Update: Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating panobinostat with everolimus in recurrent hematologic malignancies including multiple myeloma and non-Hodgkin lym…
-
CLINICAL_TRIALS trial_result · 2018-05-17Clinical Trial Update: Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 2]
Phase 2 clinical trial of panobinostat in relapsed or refractory non-Hodgkin lymphoma completed; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-05-16Clinical Trial Update: Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy [Phase 3]
Phase 3 trial comparing single-agent ofatumumab with single-agent rituximab in indolent B-cell non-Hodgkin lymphoma relapsed after rituximab…
-
CLINICAL_TRIALS trial_result · 2018-05-14Clinical Trial Update: Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT [Phase 2]
Phase 2 study in poor-risk diffuse large B-cell lymphoma using total lymphoid irradiation and anti-thymocyte globulin, followed by matched a…
-
CLINICAL_TRIALS trial_result · 2018-04-25Clinical Trial Update: Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF [Phase 1]
Phase 1 study evaluating mobilization of autologous peripheral blood stem cells using interleukin-2 and GM-CSF; the trial has completed.
-
CLINICAL_TRIALS trial_result · 2018-04-17Clinical Trial Update: Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor [NA]
Clinical trial update on biparental HLA haplotype disparate T-cell depleted transplants for patients without an HLA-compatible donor has bee…
-
CLINICAL_TRIALS trial_result · 2018-04-09Clinical Trial Update: Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) [Phase 1, Phase 2]
Phase 1/2 safety study of CAT-8015 in advanced B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia has completed enrollment with re…
-
CLINICAL_TRIALS trial_result · 2018-03-29Clinical Trial Update: Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma [Phase 2]
A multicenter Phase 2 trial sponsored by PharmaMar for relapsed/refractory aggressive non-Hodgkin lymphoma has completed enrollment and post…
-
CLINICAL_TRIALS trial_result · 2018-03-29Clinical Trial Update: Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant [Phase 1]
A Phase 1 trial from Massachusetts General Hospital evaluating recipient leukocyte infusions to prevent donor graft rejection after nonmyelo…
-
CLINICAL_TRIALS trial_result · 2018-03-12Clinical Trial Update: Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 trial results evaluate MEDI-551 (inebilizumab) in combination with immunomodulating therapies for relapsed or refractory aggressiv…
-
CLINICAL_TRIALS trial_result · 2018-03-08Clinical Trial Update: Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]
Phase 1/2 study evaluating inotuzumab ozogamicin (CMC-544) in combination with rituximab in patients with B-cell non-Hodgkin lymphoma; resul…
-
CLINICAL_TRIALS trial_result · 2018-02-14Clinical Trial Update: Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial in Non-Hodgkin lymphoma evaluating autologous followed by non-myeloablative allogeneic transplantation; study termina…
-
CLINICAL_TRIALS trial_result · 2018-01-08Clinical Trial Update: Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas [Phase 2]
Open-label Phase II trial evaluating intravenous BAY80-6946, a PI3K inhibitor, in relapsed or refractory non-Hodgkin lymphoma; the study is …